Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lifitegrast/Perfluorohexyloctane Fixed Dose Combination · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Arm 3 | ACTIVE_COMPARATOR | - |
| Arm 4 | PLACEBO_COMPARATOR | - |
| Arm 5 | PLACEBO_COMPARATOR | - |
| Arm 6 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Lifitegrast/Perfluorohexyloctane Fixed Dose Combination | DRUG | Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks |
| Lifitegrast | DRUG | Topical ocular drop of lifitegrast administered for 4 weeks |
| Perfluorohexyloctane | DRUG | Topical ocular drop of perfluorohexyloctane administered for 4 weeks |
| Vehicle | DRUG | Topical ocular drop with no active ingredients administered for 4 weeks |
Inclusion Criteria: This study will include subjects who meet all of the following inclusion criteria: * Voluntarily provide written informed consent * ≥18 years of age * Subject-reported history of DED OU for at least 6 months * Same eye satisfies the criteria for dry eye signs at both screening ...
Top 4 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | ABBV-319 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Bausch Health Companies Inc. | BHC | 1 | PHASE2 | BL1107 |
It is an investigational small molecule fixed dose combination developed by Bausch + Lomb Corporation for dry eye disease. The combination pairs lifitegrast with perfluorohexyloctane in a single formulation. It has been studied in a Phase 2 clinical trial and is not approved for marketing.
The lifitegrast/perfluorohexyloctane fixed dose combination is being developed for dry eye disease. A Phase 2 study evaluated it in adults with this condition. It remains investigational and is not approved for commercial use in any indication.
Lifitegrast, one component of the combination, targets ITGAL and ITGB2, also known as LFA-1 and CD18, and acts as an antagonist. Perfluorohexyloctane is the second component of the fixed dose formulation. The combination is designed to address dry eye disease through these combined mechanisms.
Bausch + Lomb Corporation, which trades under the ticker BLCO, is the developer of the lifitegrast/perfluorohexyloctane fixed dose combination. The company is studying the formulation for dry eye disease.
The lifitegrast/perfluorohexyloctane fixed dose combination is in Phase 2 development. One Phase 2 trial has been completed. The drug is investigational and has not been approved by the FDA for any indication.
One trial has studied the lifitegrast/perfluorohexyloctane fixed dose combination: NCT07128628, a completed Phase 2 study titled A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease. It enrolled 443 participants in the United States in a randomized, double-blind, placebo-controlled design.